History of prostate, bladder, or rectal cancer 
History of transurethral resection of the prostate (TURP), open prostate surgery, or radiofrequency or microwave therapies 
History of open bladder, rectosigmoid colon, or other pelvic surgery 
Patient is unwilling to discontinue alpha blockers 1 month after study treatment 
Patient is unwilling to discontinue 5-alph reductase inhibitors 1 month after study treatment 
Neurogenic bladder or other neurologic disorder impacting bladder function such as Parkinson's disease, multiple sclerosis, cerebral vascular accident or diabetes 
Any other confounding bladder or urethral pathology, including urethral stricture, bladder neck contracture, or bladder atonia 
Active prostatitis or urinary tract infection 
Cystolithiasis within the past 3 months 
Serum creatinine > 1.7mg/dL 
Inability to discontinue oral anticoagulant 2-5 days prior to study treatment 
Coagulation disturbances not normalized by medical treatment 
Iodinated contrast allergy that, in the opinion of the Investigator, cannot be adequately premedicated 
Gelatin allergy 
Known severe peripheral vascular disease or major iliac arterial occlusive disease 
Interest in future fertility 
Clinically significant cardiac arrhythmia or other cardiac disease (including congestive heart failure), uncontrolled diabetes mellitus, clinically significant respiratory disease, or known immunosuppression 
Other condition that the Investigator believes puts the patient at risk for a complication during the procedure       
    

NCT02396420_exc_T1
Condition
rectal cancer
NCT02396420_exc_T2
Condition
bladder cancer
NCT02396420_exc_T3
Condition
prostate cancer
NCT02396420_exc_T4
Procedure
transurethral resection of the prostate (TURP)
NCT02396420_exc_T5
Procedure
open prostate surgery
NCT02396420_exc_T6
Procedure
radiofrequency
NCT02396420_exc_T7
Procedure
microwave therapies
NCT02396420_exc_T8
Procedure
open bladder surgery
NCT02396420_exc_T9
Procedure
pelvic surgery
NCT02396420_exc_T10
Procedure
rectosigmoid colon surgery
NCT02396420_exc_T12
Drug
alpha blockers
NCT02396420_exc_T13
Drug
5-alph reductase inhibitors
NCT02396420_exc_T14
Temporal
1 month after study treatment
NCT02396420_exc_T15
Reference_point
study treatment
NCT02396420_exc_T16
Temporal
1 month after study treatment
NCT02396420_exc_T18
Condition
Neurogenic bladder
NCT02396420_exc_T19
Condition
neurologic disorder impacting bladder function
NCT02396420_exc_T20
Condition
Parkinson's disease
NCT02396420_exc_T21
Condition
multiple sclerosis
NCT02396420_exc_T22
Condition
cerebral vascular accident
NCT02396420_exc_T23
Condition
diabetes
NCT02396420_exc_T24
Scope
Neurogenic bladder Parkinson's disease, multiple sclerosis, cerebral vascular accident or diabetes
NCT02396420_exc_T25
Condition
urethral pathology
NCT02396420_exc_T27
Condition
urethral stricture
NCT02396420_exc_T28
Condition
bladder neck contracture
NCT02396420_exc_T29
Condition
bladder atonia
NCT02396420_exc_T30
Condition
bladder pathology
NCT02396420_exc_T32
Scope
bladder or urethral pathology
NCT02396420_exc_T33
Scope
urethral stricture, bladder neck contracture, or bladder atonia
NCT02396420_exc_T34
Condition
prostatitis
NCT02396420_exc_T35
Condition
urinary tract infection
NCT02396420_exc_T36
Temporal
Active
NCT02396420_exc_T37
Condition
Cystolithiasis
NCT02396420_exc_T38
Temporal
within the past 3 months
NCT02396420_exc_T39
Measurement
Serum creatinine
NCT02396420_exc_T40
Value
> 1.7mg/dL
NCT02396420_exc_T41
Drug
oral anticoagulant
NCT02396420_exc_T42
Temporal
2-5 days prior to study treatment
NCT02396420_exc_T43
Reference_point
study treatment
NCT02396420_exc_T45
Condition
Coagulation disturbances
NCT02396420_exc_T47
Procedure
medical treatment
NCT02396420_exc_T48
Qualifier
normalized
NCT02396420_exc_T49
Negation
not
NCT02396420_exc_T50
Condition
allergy
NCT02396420_exc_T51
Drug
Iodinated contrast
NCT02396420_exc_T53
Condition
allergy
NCT02396420_exc_T54
Drug
Gelatin
NCT02396420_exc_T55
Condition
peripheral vascular disease
NCT02396420_exc_T56
Qualifier
severe
NCT02396420_exc_T57
Condition
iliac arterial occlusive disease
NCT02396420_exc_T58
Qualifier
major
NCT02396420_exc_T63
Condition
cardiac arrhythmia
NCT02396420_exc_T64
Condition
cardiac disease
NCT02396420_exc_T65
Condition
congestive heart failure
NCT02396420_exc_T66
Condition
diabetes mellitus
NCT02396420_exc_T67
Qualifier
uncontrolled
NCT02396420_exc_T68
Condition
respiratory disease
NCT02396420_exc_T69
Qualifier
clinically significant
NCT02396420_exc_T72
Condition
immunosuppression